Mahindra Manulife Innovation Opportunities Fund

Long-term return data such as XIRR and rolling returns is not available, limiting return-based evaluation against category peers. The fund has posted a 4.31% calendar-year return in 2026, and category averages for context show thematic/peer SIP XIRR of 11.56% (1Y) and 16.33% (3Y). Investors should await a fuller performance history before judging relative outperformance.

The maximum drawdown of -0.11% with a 57-day duration is unusually mild for an equity fund, though two drawdown events exceeding 10% occurred historically, indicating episodic volatility. Average drawdown stands at -0.03%, suggesting generally shallow pullbacks over the measured period. Notably, the drawdown data appears incomplete and should be treated with caution rather than as evidence of low downside risk.

The top 10 holdings are diversified, with the largest position, Eternal Limited, at just 3.79% of NAV and 51 total holdings, indicating no concentrated single-stock bets. Sector exposure is spread across Pharmaceuticals & Biotechnology (10.2%), Banks (8.3%), Finance (6.7%), Transport Services (5.9%), and Auto Components (4.9%). The portfolio blends financials, healthcare, retail, and tech-adjacent names such as One97 Communications and Bajaj Finance, in line with an innovation-focused mandate.

As a thematic fund from Mahindra Manulife with a low 0.5% expense ratio, the fund competes on cost within its category, though a direct comparison of returns is not possible without available XIRR data. Category SIP XIRR averages of roughly 16-17% over 3-10 year horizons set a meaningful bar for long-term evaluation. Consistency cannot yet be assessed, and investors should monitor performance relative to these peer benchmarks as data accumulates.

This fund suits investors with a high risk tolerance and a horizon of at least 5-7 years, given that thematic funds tend to be cyclical and higher risk than diversified equity. It should be treated as a satellite allocation, typically 5-10% of an overall portfolio, rather than a core holding. The low expense ratio and diversified holdings make it a reasonable entry point for investors seeking exposure to an innovation-led theme.

• Well-diversified portfolio of 51 holdings with no stock above 3.79% of NAV, limiting single-stock risk
• Low expense ratio of 0.5%, competitive for an actively managed thematic fund
• Sector spread across pharma, banks, finance, and auto components reduces concentration risk

• No available XIRR or rolling return data, making return-based comparison against category averages (11.56% 1Y, 16.33% 3Y SIP XIRR) impossible
• Two drawdown events exceeding 10% indicate the fund can experience significant equity volatility
• Thematic mandate carries higher concentration and cyclicality risk than diversified equity funds